Nelarabine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01280 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | relapsing-remitting multiple sclerosis | KG + DL |
| 2 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 3 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 4 | botryoid-type embryonal rhabdomyosarcoma of the vagina | KG + DL |
| 5 | Hodgkins lymphoma | KG + DL |
| 6 | rhabdomyosarcoma (disease) | KG + DL |
| 7 | extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 8 | pancreatic adenocarcinoma | KG + DL |
| 9 | embryonal extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 10 | parameningeal embryonal rhabdomyosarcoma | KG + DL |
| 11 | pancreatic carcinoma with mixed differentiation | KG + DL |
| 12 | osteoclastic giant cell tumor of pancreas | KG + DL |
| 13 | solid pseudopapillary carcinoma of pancreas | KG + DL |
| 14 | Ewing sarcoma | KG + DL |
| 15 | prostate embryonal rhabdomyosarcoma | KG + DL |
| 16 | upper aerodigestive tract neoplasm | KG + DL |
| 17 | pancreatic intraductal papillary-mucinous carcinoma | KG + DL |
| 18 | mixed ductal-endocrine carcinoma of pancreas | KG + DL |
| 19 | malignant exocrine pancreas neoplasm | KG + DL |
| 20 | liver sarcoma | KG + DL |
| 21 | pancreatic signet ring cell adenocarcinoma | KG + DL |
| 22 | pancreatic intraductal papillary-mucinous neoplasm | KG + DL |
| 23 | small cell lung carcinoma | KG + DL |
| 24 | undifferentiated pancreatic carcinoma | KG + DL |
| 25 | pancreatic acinar cell cystadenocarcinoma | KG + DL |
| 26 | primary pulmonary lymphoma | KG + DL |
| 27 | pancreatic serous cystadenocarcinoma | KG + DL |
| 28 | refractory precursor T-lymphoblastic lymphoma/leukemia | KG + DL |
| 29 | pulmonary blastoma | KG + DL |
| 30 | well-differentiated fetal adenocarcinoma of the lung | KG + DL |
| 31 | pancreatic mucinous cystadenocarcinoma | KG + DL |
| 32 | Richter syndrome | KG + DL |
| 33 | myeloid leukemia | KG + DL |
| 34 | T-cell childhood lymphoblastic lymphoma | KG + DL |
| 35 | unclassified myelodysplastic syndrome | KG + DL |
| 36 | refractory cytopenia of childhood | KG + DL |
| 37 | uterine corpus sarcoma | KG + DL |
| 38 | ganglioneuroblastoma (disease) | KG + DL |
| 39 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 40 | aregenerative anemia | KG + DL |
| 41 | head and neck cancer | KG + DL |
| 42 | adenosarcoma | KG + DL |
| 43 | retroperitoneal neoplasm | KG + DL |
| 44 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 45 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 46 | fetal akinesia-cerebral and retinal hemorrhage syndrome | KG + DL |
| 47 | neuroblastoma | KG + DL |
| 48 | uterine ligament adenosarcoma | KG + DL |
| 49 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 50 | skeletal muscle neoplasm | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.